| 1 |
34554584 | Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer. | 2022 Mar |
1 |
| 2 |
33931882 | Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy. | 2021 Oct |
2 |
| 3 |
34244855 | The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. | 2021 Nov |
1 |
| 4 |
34572780 | Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. | 2021 Sep 10 |
1 |
| 5 |
32306906 | Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. | 2020 Apr 19 |
1 |
| 6 |
32377705 | HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer. | 2020 Jul |
2 |
| 7 |
32792963 | Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells via Inhibiting CDK4-RB Pathway. | 2020 |
1 |
| 8 |
30607633 | Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. | 2019 Apr |
1 |
| 9 |
29508248 | Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells. | 2018 Dec |
1 |
| 10 |
30151703 | Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. | 2018 Nov |
1 |
| 11 |
30511015 | Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. | 2018 |
1 |
| 12 |
27849562 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. | 2017 Jul |
1 |
| 13 |
28472136 | The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. | 2017 |
4 |
| 14 |
25501126 | CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. | 2015 Mar 1 |
1 |
| 15 |
26183925 | Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway. | 2015 Sep 15 |
1 |
| 16 |
26398286 | Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. | 2015 |
1 |
| 17 |
25486476 | The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. | 2014 |
1 |
| 18 |
23898052 | PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. | 2013 Aug |
1 |
| 19 |
21278246 | Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. | 2011 Mar 15 |
1 |
| 20 |
21593195 | Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. | 2011 Jul 1 |
1 |